Bioventus secured a new $400 million credit agreement, replacing its previous 2019 credit facilities, which reduces interest expenses and increases liquidity from $40 million to $100 million in revolving credit.

The global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation devices.

The global osteoarthritis therapeutics market is expected to grow from USD 9.91 billion in 2024 to USD 24.34 billion by 2034, driven by the rising prevalence of osteoarthritis and technological advancements in surgical treatments. Europe and Asia Pacific are the key regional markets.

The U.S. osteoarthritis injectables market is expected to grow significantly due to the rising prevalence of osteoarthritis, the growing geriatric population, and increased R&D activities for injectable drug development.

The article discusses how September has historically been a weak month for the stock market, but this year the S&P 500, Dow, and Nasdaq have gained over 1% so far, breaking a 5-year trend. The author recommends buying three breakout stocks that could take advantage of the broader market's upward movement: Bioventus (BVS), Great Lakes Dredge & Dock (GLDD), and AxoGen (AXGN).

The global pseudarthrosis treatment market is expected to grow at a CAGR of 4.6% from 2024 to 2034, driven by advancements in biocompatible materials and positive government reimbursement programs. North America and South Asia & Pacific are the key regions driving market growth.

Corcept Therapeutics' (CORT) shares have gained over 45% in the past six months, driven by strong performance of its sole-marketed drug Korlym and progress in the development of its lead pipeline candidate relacorilant for treating Cushing's syndrome.

The U.S. autoimmune disease diagnostics market is expected to reach $3.01 billion by 2030, driven by the rising incidence of autoimmune diseases and advancements in diagnostic technologies. Localized autoimmune disease diagnostics and antinuclear antibody tests are expected to dominate the market.

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.

Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.

Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.